Notícias

Eli Lilly stock toppled Monday after a patient taking its new weight-loss pill, Foundayo, experienced liver failure.

The benchmark US stock measures were mostly pointing lower before the opening bell Monday as investo

It looks like Pfizer Inc. ( NYSE:PFE ) is about to go ex-dividend in the next three days. The ex-dividend date is one...

Although excitement over the biotech’s “Protac” protein degrader is being tempered by narrower-than-expected clinical benefit, R&D in the field is heating up.

Investors won’t get too much of a respite from a big week trading the AI boom, with Palantir, Advanced Micro Devices, and CoreWeave reporting earnings. A bevy of data about the U.S. jobs market will also be watched closely, culminating in April nonfarm payroll numbers Friday.

Shares of Pfizer are down 50% from their 2021 high, and the yield is an alluring 6.4%.

ON Semiconductor, Pfizer, Uber, McDonald’s, and many more will report earnings this week. Economic releases will include the April jobs report and purchasing managers index.

Pfizer Inc. (NYSE:PFE) ranks among the best low-risk investments in May 2026. On April 13, Guggenheim reaffirmed a Buy rating and a $36 price target for Pfizer Inc. (NYSE:PFE) as the firm revised its financial forecast ahead of the company’s Q1 earnings announcement on May 5. The firm anticipates first-quarter revenues of around $13.8 billion, […]

Novavax (NVAX) is in focus after outlining a move toward a licensing and royalty model, supported by partnerships with Sanofi and Pfizer, while investors watch for a Phase 3 COVID influenza combo readout. See our latest analysis for Novavax. The licensing pivot and upcoming COVID influenza combo catalyst come after a mixed period for investors, with a 12.76% year-to-date share price return alongside a 25.43% one-year total shareholder return, but a very large five-year total shareholder loss...

Beneath Eli Lilly's (LLY) headline numbers lies a structural business model shift that the broader market seems to currently undervalue, driven in part by a recent valuation penalty following Novo Nordisk's faster initial prescription ramp for its oral therapy. While early volume data favors the competitor’s established brand capture, the central equity debate remains focused on the friction between high demand and pricing pressure from pharmacy benefit managers. Critics highlight dropping reali

Blue-chip stocks are shares of large, well-established, financially stable companies with a consistent and reliable performance history. They are often considered less risky and are a popular choice for long-term investors. Additionally, nearly all leaders in the category pay dependable, recurring dividends each quarter, regardless of the state of the economy. The term “blue chip” ... 5 Quality Passive Income Blue-Chips That All Yield 5% and More Safely

Gross margin above 82% during price cuts signals structural pricing power

If you are wondering whether Pfizer's current share price properly reflects its long term potential, the recent share performance gives you a useful starting point. At a last close of US$26.70, the stock has moved 0.1% over the past week, dipped 4.9% over the last 30 days, is up 6.0% year to date, and has risen 19.7% over the past year, with 3 year and 5 year returns of 16.3% and 13.4% declines respectively. Recent headlines around Pfizer have focused on its broader position in...

Pfizer Inc. (NYSE:PFE) is included among the 10 Innovative Dividend Stocks to Buy Right Now. On April 28, Morgan Stanley reiterated an Equal Weight rating on Pfizer Inc. (NYSE:PFE). It also set a $28 price target on the stock. The firm said that Pfizer has reached a settlement with all three Vyndamax generic filers. The […]

Pfizer Inc. (NYSE:PFE) is one of the 10 Best Medical Stocks to Buy Under $30. On April 20, Pfizer Inc. (NYSE:PFE) announced, together with Astellas Pharma Inc., that the US Food and Drug Administration has accepted a supplemental Biologics License Application (sBLA) for Priority Review. The application is for the use of PADCEV (enfortumab vedotin-ejfv) […]

Alnylam stock popped Thursday on a solid first-quarter beat for its Pfizer-rivaling heart disease drug, Amvuttra.